Immune Response of Haemodialysis Patients Post Covid-19 Vaccination
NCT04872751 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 425
Last updated 2021-05-07
Summary
The purpose of this study is to assess immune response of end stage renal failure patients after Covid 19 vaccination
Conditions
- Immune Response Post Covid 19 Vaccination
Sponsors & Collaborators
-
Penang Hospital, Malaysia
lead OTHER_GOV
Principal Investigators
-
LokeMeng Ong · Penang Hospital
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-04-27
- Primary Completion
- 2022-04-30
- Completion
- 2022-04-30
Countries
- Malaysia
Study Locations
More Related Trials
-
Impact Of Kidney Failure On The Regulation Of Humoral Response To Vaccination
NCT06635525 ·Status: RECRUITING
-
COVID-19 Vaccine Boosters in Patients With CKD
NCT05022329 ·Status: TERMINATED ·Phase: PHASE2/PHASE3
-
Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease
NCT01974817 ·Status: COMPLETED ·Phase: PHASE4
-
A Pilot Study to Evaluate ZADAXIN's® (Thymalfasin) Ability to Enhance Immune Response to the H1N1sw Influenza Vaccine
NCT01031966 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects
NCT03235375 ·Status: COMPLETED ·Phase: PHASE1
-
Safety Evaluation of Linear and Macrocyclic Gadolinium Based Contrast Agents for Patients With Mild to Moderate Renal Insufficiency Undergoing Enhanced Magnetic Resonance Imaging
NCT04776187 ·Status: UNKNOWN ·Phase: PHASE4
-
Efficacy and Safety in Chinese Patients with Immunoglobulin a Nephropathy (IgAN) Who Have Completed Study Nef-301
NCT05534919 ·Status: COMPLETED ·Phase: PHASE3
-
The Effect of Daratumumab in Patients with Monoclonal Gammopathy of Renal Significance (MGRS) in Finland
NCT06889948 ·Status: RECRUITING ·Phase: PHASE2
-
The Safety of Paxlovid in Hemodialysis Patients With Covid-19
NCT05366192 ·Status: COMPLETED ·Phase: PHASE4
-
Pharmacokinetics and Safety of GST-HG171 Tablets in Subjects With Impaired and Normal Renal Function
NCT06106126 ·Status: UNKNOWN ·Phase: NA
-
Eculizumab in Pediatric and Adult Participants With Atypical Hemolytic Uremic Syndrome (aHUS) in China
NCT05876351 ·Status: COMPLETED ·Phase: PHASE3
-
An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy
NCT06469190 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
A Research Study of How the Medicine Ziltivekimab Works in the Body of Chinese Men and Women With Kidney Disease and Inflammation
NCT05379829 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment
NCT04527328 ·Status: COMPLETED ·Phase: NA
-
Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus
NCT05885737 ·Status: COMPLETED ·Phase: PHASE3
-
CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis
NCT03428594 ·Status: COMPLETED ·Phase: PHASE3
-
Paired Marrow Aspirations to Assess Assays in Sensitized Renal Allograft Recipients
NCT01150487 ·Status: COMPLETED ·Phase: NA
-
Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation
NCT03373461 ·Status: COMPLETED ·Phase: PHASE2
-
The Effect of Sevelamer Carbonate on Serum Trimethylamine-n-Oxide (TMAO) Level in Patients With Chronic Kidney Disease (CKD) Stage 3b-4
NCT03596749 ·Status: UNKNOWN ·Phase: PHASE3
-
Study of FG-4592 in Subjects With End-Stage Renal Disease Receiving Maintenance Hemodialysis in China
NCT01596855 ·Status: COMPLETED ·Phase: PHASE2
-
Medicine-induced Cardiac Hemodialysis on COVID-19
NCT05711810 ·Status: COMPLETED ·Phase: PHASE4
-
NI-0401 in Patients With Acute Renal Allograft Rejection
NCT00805909 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
HMG-CoA Reductase add-on in Chronic Kidney Disease Patients With Proteinuria
NCT03550859 ·Status: UNKNOWN ·Phase: PHASE4
-
Study of FG-4592 in Subjects With Chronic Kidney Disease in China
NCT01599507 ·Status: COMPLETED ·Phase: PHASE2
-
Obinutuzumab in the Management of Idiopathic Membranous Nephropathy
NCT05845762 ·Status: UNKNOWN